Polar Capital Holdings PLC Biomarin Pharmaceutical Inc Transaction History

Polar Capital Holdings PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $6.38 Million - $7.09 Million	-75,000 Reduced 17.65%	350,000 $31 Million
Q1 2023 Dec 13, 2023	BUY	$87.74 - $117.27 $6.58 Million - $8.8 Million	75,000 Added 21.43%	425,000 $41.3 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $21.9 Million - $29.3 Million	250,000 Added 142.86%	425,000 $41.3 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $4.05 Million - $5.43 Million	-50,000 Reduced 22.22%	175,000 $18.1 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $19.7 Million - $23.9 Million	-275,000 Reduced 55.0%	225,000 $18.6 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $27.9 Million - $34.8 Million	375,000 Added 300.0%	500,000 $38.6 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $16.8 Million - $20.4 Million	-225,000 Reduced 64.29%	125,000 $9.44 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $25.4 Million - $31.6 Million	350,000 New	350,000 $30.7 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.